Zobrazit v EDS

Epidemiology, treatment, and survival in small cell lung cancer in Spain: Data from the Thoracic Tumor Registry

Uloženo v:
Podrobná bibliografie
Název: Epidemiology, treatment, and survival in small cell lung cancer in Spain: Data from the Thoracic Tumor Registry
Autoři: Franco, Fernando, Carcereny, Enric, Guirado, Maria, Ortega, Ana L., López-Castro, Rafael, Rodríguez-Abreu, Delvys, García-Campelo, Rosario, Del Barco, Edel, Juan, Oscar, Aparisi, Francisco, González-Larriba, Jose L., Domine, Manuel, Trigo, Jose M., Cobo, Manuel, Cerezo, Sara, Calzas, Julia, Massutí, Bartomeu, Bosch-Barrera, Joaquim, García Coves, Paola, Domènech, Marta, Provencio, Mariano
Přispěvatelé: Franco,F, Provencio,M Hospital Universitario Puerta de Hierro-Majadahonda, Madrid, Spain. Carcereny,E, Domènech,M Catalan Institute of Oncology, Hospital Universitari Germans Trias i Pujol, B-ARGO, IGTP, Badalona, Spain. Guirado,M, García Coves,P Hospital General Universitario de Elche, Elche, Spain. Ortega,AL Hospital Universitario de Jaén, Jaén, Spain. López-Castro,R Hospital Clínico Universitario de Valladolid, Valladolid, Spain. Rodríguez-Abreu,D Hospital Universitario Insular de Gran Canaria, Las Palmas de Gran Canaria, Spain. García-Campelo,R Complejo Hospitalario Universitario A Coruña, A Coruña, Spain. Del Barco,E Hospital Universitario de Salamanca, Salamanca, Spain. Juan,O Hospital Universitario y Politécnico La Fe, Valencia, Spain. Aparisi,F Hospital General de Valencia, Valencia, Spain. González-Larriba,JL Hospital Universitario Clínico San Carlos, Madrid, Spain. Domine,M Hospital Universitario Fundación Jiménez Díaz, IIS-FJD, Madrid, Spain. Trigo,JM, Cobo,M Unidad de Gestión Clínica Intercentros de Oncología Médica, Hospitales Universitarios Regional y Virgen de la Victoria, IBIMA, Málaga, Spain. Cerezo,S Hospital General La Mancha Centro, Alcázar de San Juan, Spain. Calzas,J Hospital Universitario de Fuenlabrada, Fuenlabrada, Spain. Massutí,B Hospital General Universitario de Alicante, Alicante, Spain. Bosch-Barrera,J Catalan Institute of Oncology, Girona, Spain., The TTR registry was supported by Fundación GECP, AstraZeneca, Novartis, Roche, the European Union’s Horizon 2020 research and innovation program (CLARIFY 875160).
Informace o vydavateli: Public Library of Science
Rok vydání: 2021
Sbírka: Sistema Sanitario Público de Andalucía (SSPA): Repositorio
Témata: Epidemiology, Treatment, Survival, Small cell lung cancer, Spain, Thoracic tumor, Epidemiología, Terapéutica, Supervivencia (salud pública), Carcinoma pulmonar de células pequeñas, España, Neoplasias torácicas, Medical Subject Headings::Persons::Persons::Age Groups::Adult::Aged, Medical Subject Headings::Analytical, Diagnostic and Therapeutic Techniques and Equipment::Therapeutics::Combined Modality Therapy, Medical Subject Headings::Check Tags::Female, Medical Subject Headings::Health Care::Environment and Public Health::Public Health::Epidemiologic Methods::Epidemiologic Study Characteristics as Topic::Epidemiologic Studies::Cohort Studies::Follow-Up Studies, Medical Subject Headings::Organisms::Eukaryota::Animals::Chordata::Vertebrates::Mammals::Primates::Haplorhini::Catarrhini::Hominidae::Humans, Medical Subject Headings::Diseases::Neoplasms::Neoplasms by Site::Thoracic Neoplasms::Respiratory Tract Neoplasms::Lung Neoplasms, Medical Subject Headings::Check Tags::Male, Medical Subject Headings::Persons::Persons::Age Groups::Adult::Middle Aged, Diagnostic and Therapeutic Techniques and Equipment::Diagnosis::Prognosis, Diagnostic and Therapeutic Techniques and Equipment::Investigative Techniques::Epidemiologic Methods::Epidemiologic Study Characteristics as Topic::Epidemiologic Studies::Cohort Studies::Retrospective Studies, Medical Subject Headings::Diseases::Neoplasms::Neoplasms by Site::Thoracic Neoplasms::Respiratory Tract Neoplasms::Lung Neoplasms::Bronchial Neoplasms::Carcinoma, Bronchogenic::Small Cell Lung Carcinoma, Medical Subject Headings::Geographical Locations::Geographic Locations::Europe::Spain, Medical Subject Headings::Health Care::Population Characteristics::Demography::Vital Statistics::Mortality::Survival Rate
Popis: Background Small-cell lung cancer (SCLC) is an aggressive disease with high metastatic potential and poor prognosis. Due to its low prevalence, epidemiological and clinical information of SCLC patients retrieved from lung cancer registries is scarce. Patients and methods This was an observational multicenter study that enrolled patients with lung cancer and tho racic tumors, recruited from August 2016 to January 2020 at 50 Spanish hospitals. Demo graphic and clinical data, treatment patterns and survival of SCLC patients included in the Thoracic Tumor Registry (TTR) were analyzed. Results With a total of 956 cases, the age of 64.7 ± 9.1 years, 78.6% were men, 60.6% smokers, and ECOG PS 0, 1 or 2 in 23.1%, 53.0% and 23.8% of cases, respectively. Twenty per cent of patients had brain metastases at the diagnosis. First-line chemotherapy (CT), mainly carboplatin or cisplatin plus etoposide was administered to >90% of patients. In total, 36.0% and 13.8% of patients received a second and third line of CT, respectively. Median overallsurvival was 9.5 months (95% CI 8.8–10.2 months), with an estimated rate of 70.3% (95% CI 67.2–73.4%), 38.9% (95% CI 35.4–42.4%), and 14.8% (95% CI 11.8–17.8%) at 6, 12 and 24 months respectively. Median progression-free survival was 6.3 months. Higher mor tality and progression rates were significantly associated with male sex, older age, smoking habit, and ECOG PS 1–2. Long-term survival (> 2 years) was confirmed in 6.6% of patients,showing a positive correlation with better ECOG PS, poor smoking and absence of certain metastases at diagnosis. Conclusion This study provides an updated overview of the clinical situation and treatment landscape of ES-SCLC in Spain. Our results might assist oncologists to improve current clinical practice towards a better prognosis for these patients. ; Yes
Druh dokumentu: article in journal/newspaper
Popis souboru: application/pdf; application/vnd.openxmlformats-officedocument.wordprocessingml.document
Jazyk: English
ISSN: 1932-6203
Relation: https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0251761; Franco F, Carcereny E, Guirado M, Ortega AL, López-Castro R, Rodríguez-Abreu D, et al. Epidemiology, treatment, and survival in small cell lung cancer in Spain: Data from the Thoracic Tumor Registry. PLoS One. 2021 Jun 2;16(6):e0251761; http://hdl.handle.net/10668/4053; PMC8171958
DOI: 10.1371/journal.pone.0251761
Dostupnost: http://hdl.handle.net/10668/4053
https://doi.org/10.1371/journal.pone.0251761
Rights: Atribución 4.0 Internacional ; http://creativecommons.org/licenses/by/4.0/ ; open access
Přístupové číslo: edsbas.BF63826F
Databáze: BASE
Popis
Abstrakt:Background Small-cell lung cancer (SCLC) is an aggressive disease with high metastatic potential and poor prognosis. Due to its low prevalence, epidemiological and clinical information of SCLC patients retrieved from lung cancer registries is scarce. Patients and methods This was an observational multicenter study that enrolled patients with lung cancer and tho racic tumors, recruited from August 2016 to January 2020 at 50 Spanish hospitals. Demo graphic and clinical data, treatment patterns and survival of SCLC patients included in the Thoracic Tumor Registry (TTR) were analyzed. Results With a total of 956 cases, the age of 64.7 ± 9.1 years, 78.6% were men, 60.6% smokers, and ECOG PS 0, 1 or 2 in 23.1%, 53.0% and 23.8% of cases, respectively. Twenty per cent of patients had brain metastases at the diagnosis. First-line chemotherapy (CT), mainly carboplatin or cisplatin plus etoposide was administered to >90% of patients. In total, 36.0% and 13.8% of patients received a second and third line of CT, respectively. Median overallsurvival was 9.5 months (95% CI 8.8–10.2 months), with an estimated rate of 70.3% (95% CI 67.2–73.4%), 38.9% (95% CI 35.4–42.4%), and 14.8% (95% CI 11.8–17.8%) at 6, 12 and 24 months respectively. Median progression-free survival was 6.3 months. Higher mor tality and progression rates were significantly associated with male sex, older age, smoking habit, and ECOG PS 1–2. Long-term survival (> 2 years) was confirmed in 6.6% of patients,showing a positive correlation with better ECOG PS, poor smoking and absence of certain metastases at diagnosis. Conclusion This study provides an updated overview of the clinical situation and treatment landscape of ES-SCLC in Spain. Our results might assist oncologists to improve current clinical practice towards a better prognosis for these patients. ; Yes
ISSN:19326203
DOI:10.1371/journal.pone.0251761